Status:
ENROLLING_BY_INVITATION
Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Haemophilia
Eligibility:
All Genders
Brief Summary
This study will help to better understand the course of disease in people with haemophilia (A or B \[with or without inhibitors\]) and the haemophilia care scenario in the selected countries and the e...
Eligibility Criteria
Inclusion
- For Experienced/Senior Treating Physicians
- Experienced/senior haematologist treating haemophilia (adult or paediatric) or physician treating patients with haemophilia. (PWH), with greater than 5 years of experience.
- Able to communicate in English or country specific language.
- Agree/sign informed consent before data collection. For Patients Organisations
- Patient organisation supporting haemophilia.
- Expert having greater than 3 years of work experience with the patient organisation.
- Expert level understanding of haemophilia landscape and care pathway in the relevant country.
- Able to communicate in English or country specific language.
- Agree/sign informed consent before data collection. For Patients/Caregivers
- Patients of all age groups, diagnosed with haemophilia A or haemophilia B (with or without inhibitors) for greater than 2 years.
- For patients less than 18 years of age (\*less than 19 years for South Korea), their caregivers aged greater than or equal to 18 years (\*greater than or equal to19 years for South Korea) should sign the informed consent.
- \*For South Korea, the adult age is 19 years.
- Able to communicate in English or country specific language.
- Agree/sign informed consent before data collection.
Exclusion
- There is no explicit exclusion criterion in this study, thus any participants group who answers "no" to any of the inclusion criteria will be excluded from the study.
Key Trial Info
Start Date :
January 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 19 2025
Estimated Enrollment :
244 Patients enrolled
Trial Details
Trial ID
NCT07163260
Start Date
January 31 2025
End Date
December 19 2025
Last Update
October 24 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Bangalore, Karnataka, India, 560 066
2
Novo Nordisk Investigational Site
Kuala Lumpur, Malaysia, 50470
3
Novo Nordisk Investigational Site
Seoul, South Korea
4
Novo Nordisk Investigational Site
Bangkok, Thailand, 10500